Medical Condition News

RSS

Novel technology to grow new primordial lung progenitors

Researchers at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have derived a population of pure lung and thyroid progenitor cells in vitro that successfully mimic the developmental milestones of lung and thyroid tissue formation.

6 Apr 2012

Three genes within human embryonic stem cells regulate development

Yale researchers show in detail how three genes within human embryonic stem cells regulate development, a finding that increases understanding of how to grow these cells for therapeutic purposes.

6 Apr 2012

Poor mental health can lead to heart problems and death in dialysis patients

Dialysis patients whose mental health deteriorates over time have an increased risk of developing heart problems and dying prematurely, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

6 Apr 2012

Tonix completes TNX-102 pharmacokinetic study on fibromyalgia syndrome

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system completed a pharmacokinetic (PK) study of the first formulation of its lead drug, TNX-102, for the treatment of fibromyalgia syndrome.

6 Apr 2012

Sucampo announces positive results from lubiprostone phase 3 trial on OBD

Sucampo Pharmaceuticals, Inc. today announced positive top-line results from an open-label phase 3 clinical trial designed to evaluate the long-term safety and efficacy of lubiprostone in opioid-induced bowel dysfunction (OBD) patients with chronic, non-cancer-related pain.

6 Apr 2012

Cognitive and psychiatric impairments common among long-term ALI survivors

Cognitive and psychiatric impairments are common among long-term survivors of acute lung injury (ALI), and these impairments can be assessed using a telephone-based test battery, according to a new study.

6 Apr 2012

Positive effect of tafamidis on neurological degeneration

Tafamidis meglumine was approved in November 2011 for the treatment of transthyretin amyloidosis in adults. This rare disorder is caused by a defective gene and is associated with progressive nerve damage (neurological degeneration) that tafamidis is supposed to delay.

6 Apr 2012

Zalicus' cHTS platform identifies synergistic drug combinations for treatment of cancer

Adenosine A2A and beta-2 adrenergic receptor agonists are highly synergistic and selective novel agents that enhance glucocorticoid activity in B-cell malignancies such as multiple myeloma and, importantly, can synergize in combination with current multiple myeloma treatment regimens such as melphalan, lenalidomide, bortezomib and doxorubicin.

6 Apr 2012

FuelCo campaign raises $20,000 to benefit cure-focused work of DRI

In six short weeks, FuelCo, which operates various retail and convenience stores throughout Connecticut and New York, sold $20,000 worth of scannable cards recently to benefit the cure-focused work of the Diabetes Research Institute.

6 Apr 2012

Purdue Pharma launches Intermezzo for middle-of-the-night insomnia

Purdue Pharma L.P. announced today that Intermezzo (zolpidem tartrate) sublingual tablet CIV is now available in 1.75 mg and 3.5 mg dosage strengths by prescription in retail pharmacies nationwide.

6 Apr 2012

Sweetheart Ball raises $280,000 to benefit cancer programs and services

The Fifteenth Annual Sweetheart Ball was held on Saturday, February 25, at Eagle Oaks Golf and Country Club in Farmingdale and raised a record breaking $280,000.

6 Apr 2012

FDA clears CooperVision's Avaira Toric contact lenses for astigmatism

CooperVision, Inc. today announced that the U.S. Food and Drug Administration has granted a Special 510(k) clearance for CooperVision's Avaira Toric two-week silicone hydrogel contact lenses for astigmatism.

6 Apr 2012

Collaborative Cross project to develop lab mice with increased genetic diversity

With a 95 percent genomic similarity to humans, mice have long been used to learn about the genetic causes of human disease. Once researchers can shine a light on the genetic factors that cause disease in mice, they can start to develop prevention and treatment options to protect the human population.

6 Apr 2012

Astellas' mirabegron for OAB receives FDA advisory committee approval

Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the Reproductive Health Drugs Advisory Committee of the U.S. Food and Drug Administration voted that the overall risk/benefit assessment supports approval of mirabegron for the treatment of overactive bladder.

6 Apr 2012

Spectrum’s apaziquone Phase 3 trials on bladder cancer do not meet primary endpoint

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the two double blind, randomized, placebo controlled, Phase 3 clinical trials for apaziquone did not meet their primary endpoint of a statistically significant difference in the rate of tumor recurrence at 2 years between the two arms.

6 Apr 2012

Evergreen Healthcare employs transanal endoscopic microsurgery for colorectal tumor removal

Evergreen Healthcare today announced that it has successfully integrated a colorectal procedure called transanal endoscopic microsurgery to its growing suite of minimally invasive surgical options, reducing the need for major surgery and providing patients with faster recovery times.

6 Apr 2012

Steps to reduce risk of social media sites among teenagers

While social media has made connecting and communicating with anyone at any time as easy as pie, it also has altered teen's social skills and behaviors. Sites such as Facebook, Twitter and MySpace have proven to be great tools to expedite the development of empathy, encourage task-switching or even bring somewhat shy individuals a little more out of their shells. However, social media sites have also fostered a host of psychological and behavioral problems.

6 Apr 2012

Towards a drug to control cystic fibrosis

Harvard stem cell researchers at Massachusetts General Hospital (MGH) have taken a critical step in making possible the discovery in the relatively near future of a drug to control cystic fibrosis (CF), a fatal lung disease that claims about 500 lives each year, with 1,000 new cases diagnosed annually.

6 Apr 2012

CHL's inflammation biomarkers to be showcased at TEDMED 2012 conference

Cleveland HeartLab Inc. (CHL), a rapidly growing specialty clinical laboratory and cardiovascular disease management company, today announced that its panel of inflammation biomarkers will be featured at next week's TEDMED 2012 conference in Washington.

6 Apr 2012

Key finding in regulation of intraocular pressure in glaucoma

A six-year collaboration between two faculty members of Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine has yielded new insight regarding the regulation of intraocular pressure (IOP) in glaucoma - an irreversible blinding disease that causes progressive visual impairment due to optic nerve damage and is the leading cause of blindness worldwide.

6 Apr 2012